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Abstract
Purpose Following the first wave of the COVID-19 pandemic in early 2020, the easing of strict measures to reduce its spread has
led to a resurgence of cases in many countries at both the national and local level. This article addresses how guidance for
ophthalmologists on managing patients with retinal disease receiving intravitreal injections of anti-vascular endothelial growth
factor (VEGF) during the pandemic should be adapted to the local epidemic pressure, with more or less stringent measures
implemented according to the ebb and flow of the pandemic.
Methods The Vision Academy’s membership of international retinal disease experts analyzed guidance for anti-VEGF intravit-
real injections during the COVID-19 pandemic and graded the recommendations according to three levels of increasing epidemic
pressure. The revised recommendations were discussed, refined, and voted on by the 14-member Vision Academy Steering
Committee for consensus.
Results Protocols to minimize the exposure of patients and healthcare staff to COVID-19, including use of personal protective
equipment, physical distancing, and hygiene measures, should be routinely implemented and intensified according to local
infection rates and pressure on the hospital/clinic or healthcare system. In areas with many COVID-19-positive clusters, addi-
tional measures including pre-screening of patients, postponement of non-urgent appointments, and simplification of complex
intravitreal anti-VEGF regimens should be considered. Treatment prioritization for those at greatest risk of irreversible vision loss
should be implemented in areas where COVID-19 cases are increasing exponentially and healthcare resources are strained.
This article is part of a topical collection on Perspectives on COVID-19.
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Conclusion Consistency in monitoring of local infection rates and adjustment of clinical practice accordingly will be required as
we move forward through the COVID-19 era. Ophthalmologists must continue to carefully weigh the risk–benefits to minimize
the exposure of patients and healthcare staff to COVID-19, ensure that patients receive sight-saving treatment, and avoid the
potential long-term impact of prolonged treatment postponement.
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Introduction
Following the rapid spread of the novel coronavirus SARS-
CoV-2 across the world in early 2020, the ophthalmic com-
munity had to quickly adjust clinical practice in response to
high infection rates, mounting pressure on healthcare systems,
and implementation of restrictions or “lockdowns” that pre-
cluded many patients from attending appointments.
As we navigate through the current phase of the pandemic,
where infection rates are once again accelerating in many
countries and vary largely between regions, ophthalmologists
must be prepared to respond quickly to the changing epidemic
pressure in their local area to ensure that patients receive sight-
saving ophthalmic care, while still ensuring the safety of pa-
tients and staff.
The Vision Academy previously published guidance for
managing patients receiving anti-vascular endothelial growth
factor (VEGF) injections during the acute phase of the
COVID-19 pandemic [1]. As we adjust to the “new normal”
of ophthalmic care in the era of COVID-19, we consider how
this guidance should be implemented according to the local ep-
idemic pressure. This article provides practical guidance for the
management of patients receiving anti-VEGF injections while
the threat of COVID-19 remains, and describes how measures
should be escalated when infection rates rise and healthcare re-
sources become stretched, to ensure prioritization of treatment
for those with the greatest medical need. Conversely, this article
also indicates how measures can be de-escalated when the epi-
demic pressure decreases.
Methods
The Vision Academy is an international group of more than
90 retinal physicians who work together to share existing
skills and knowledge, and provide collective recommenda-
tions on clinical challenges in areas where there is a lack of
conclusive evidence in the literature [2].
Vision Academy guidance for anti-VEGF intravitreal injec-
tions during the COVID-19 pandemic was first published on-
line in April 2020 [1], during the first “wave” of the pandemic.
This guidance was reviewed during the Vision Academy
Annual Meeting in August 2020, where members were asked
to validate and decide which recommendations should be im-
plemented at three levels of local epidemic pressure. Following
contributions from the membership, the revised recommenda-
tions were analyzed, refined, and voted on by the 14-member
Vision Academy Steering Committee for consensus.
What is Known
Easing of strict measures to reduce the spread of COVID-19 has led to a resurgence of cases in many 
countries 
What is New
Measures to ensure the safety of patients and staff, and the sustainability of healthcare resources, should be
intensified according to the local epidemic pressure  
Postponing non-urgent appointments, simplifying complex intravitreal anti-VEGF regimens, and 
prioritizing treatment for those with the greatest medical need should be considered in situations of high
and extreme epidemic pressure 
Patients with DME and BRVO who had their treatment postponed >6 months during the initial wave
of the COVID-19 pandemic should have their treatment maintained wherever possible to avoid risk of 
permanent visual changes    
Key messages
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Guiding principles
Ensuring the safety of healthcare staff and patients should be a
key consideration in all decision-making, and practices should
be reviewed regularly to account for changing local epidemic
pressure. Vigilance in identifying suspect cases of COVID-19
remains essential, with symptoms including dry cough, fever,
and fatigue, or less commonly, loss of taste or smell, head-
ache, muscle pain, sore throat, conjunctivitis, dyspnea, nasal
congestion, skin rash, or diarrhea [3]. Patients receiving intra-
vitreal injections of anti-VEGF are often elderly and/or dia-
betic, both of which are characteristics associated with a high
risk of COVID-19 complications and hospitalization [4, 5].
While it is important to minimize the exposure of vulnerable
patients to avoidable risk, prevention of irreversible vision
loss through continuation of care should be practiced wherev-
er possible.
Although our previous guidance [1] discussed the potential
for short-term deprioritization of certain cases of diabetic mac-
ular edema (DME) and branch retinal vein occlusion (BRVO)
due to a reduced likelihood for irreversible vision loss [6, 7], it
is important to consider that many patients with DME and
BRVOwill have already had their treatment postponed during
the initial wave of the COVID-19 pandemic, and it is possible
that further deferral of treatment may lead to permanent visual
changes.
Overall, patients receiving intravitreal injections require
clear communication and advice to ensure they feel supported
and reassured that their vision remains a key priority.
Extensive considerations can be found in previously pub-
lished guidance [1]. A summary of the recommendations is
shown in Table 1.
Low epidemic pressure situations
The effective reproduction number, Rt, is the expected
number of new infections generated at time t by each
infectious case, in a population where some individuals
may no longer be susceptible [15, 16]. Rt has been widely
used to monitor the spread of COVID-19, with achieving
Rt < 1 being a key goal to prevent the exponential spread
of infection [16–19]. When considering the following rec-
ommendations, low epidemic pressure indicates situations
where Rt is significantly < 1 but herd immunity through
mass vaccination has not yet been achieved. In such situ-
ations, some physical distancing measures are likely to be
in place, but these would constitute the “new normal”
until a suitable vaccine or treatment becomes available.
Recommendations for situations of low epidemic pressure
are also valid in situations with a higher alert level.
General considerations
COVID-19 remains a threat even in areas where the infection
rate is low, and vigilance must be practiced irrespective of the
current situation to help prevent escalation of the infection
rate. It is essential that safety and hygiene practices are imple-
mented consistently throughout the patient journey to prevent
the cycle of transmission (Table 1) [20].
Prioritizing patients according to medical need
Even in situations of low epidemic pressure, ophthalmology
clinics may be unable to run at full capacity due to physical
distancing measures. If prioritization of patients is required,
steps should be taken to ensure the patient is fully informed
and that legal, regulatory, and future capacity considerations
are appropriately assessed (Table 1). If necessary, treatment
visits should be prioritized over monitoring visits, with self-
monitoring procedures implemented where possible (Table 1)
[21].
Postponing appointments for patients with confirmed or
suspected COVID-19 is strongly recommended in all cases,
with the exception of emergency intervention to prevent se-
vere vision loss.
Measures to triage and support patients, and inform
them of important safety practices such as use of masks
and physical distancing [9–11] have been discussed pre-
viously [1]. In addition to these measures, it may be ben-
eficial to provide a “Dear Patient” letter to all patients that
reiterates the importance of attending appointments and
offers advice on what to do should they be unable to
attend [8].
Reducing exposure during the patient visit
Specific considerations to reduce the exposure of patients and
staff to COVID-19, including use of personal protective
equipment (PPE), physical distancing, and other measures to
reduce exposure in waiting rooms, have previously been de-
scribed at length [1] and are summarized in Table 1.
Importantly, use of masks and physical distancing are strongly
encouraged due to their association with a reduced risk of
infection in those exposed to COVID-19-positive individuals
[9]. Risk reduction appears to be strongest with N95 or equiv-
alent masks; both N95 and surgical masks may offer better
protection from infection than single-layer masks. Physical
distancing of at least 1 m is associated with a significant re-
duction in risk of infection, which may be further reduced by
distancing by 2 m, and should be implemented wherever fea-
sible [9].
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Table 1 Guidance for anti-VEGF intravitreal injections in retinal disease patients according to local COVID-19 epidemic pressure [1]
Low epidemic pressure situationsa
General considerations
• Regularly monitor medical/healthcare staff for signs and symptoms of infection
• Provide staff with regular training on use of PPE and other safety practices
• Consistently implement and follow personal, facility, and instrument hygiene/disinfection rules
Prioritizing patients according to medical need
• Discuss treatment prioritization with the patient, taking into account the legal/regulatory environment, status of the epidemic, and the capacity to reschedule
postponed procedures
• If necessary, prioritize treatment visits over monitoring visits
o Inform patients on how to self-monitor their vision/implement the use of home monitoring technologies, if possible
• Defer appointments of COVID-19-positive/suspect patients, except for cases requiring emergency intervention to prevent imminent danger of severe vision loss
• Prior to the appointment, inform patients about the safety and hygiene measures in place
• Provide a “Dear Patient” letter that reiterates the importance of attending appointments and offers advice on what to do should they be unable to attend [8]
• Provide patient support via an emergency contact number manned by a senior ophthalmologist
Reducing exposure during the patient visit
• Ensure wearing of face masks at all times (patients and staff) [9–11]
o An N95 or FFP2 mask is preferred or a surgical mask where these are not available
• Ensure good ventilation in all rooms [12]
• Limit exposure in waiting rooms by use of masks, 1m or 2 m physical distancing, spacing out appointments, allowing only one accompanying adult if necessary,
and promoting queuing outside the waiting room
Reducing exposure during the patient examination
• Wear PPE for patients who are COVID-19-positive/suspect, or for all patients, as directed by local authorities
• Keep examinations as brief as possible and consider implementing physical distancing measures between patients and staff
• Thoroughly disinfect hands and equipment, including keyboards, between patients
• Affix large plastic/plexiglass shields to slit lamps and OCT
• To reduce risk of contamination, tape the upper edges of the face mask during intravitreal injection procedures
• For COVID-19-positive/suspect patients, emergency surgery/intervention should take place in a facility with appropriate safety measures and PPE in place
High epidemic pressure situationsb, in addition to the above recommendations
Prioritizing patients according to medical need
• Pre-screen patients by phone to identify symptomatic/suspected COVID-19-positive patients (or relatives/caregivers)
• Prioritize and maintain treatment schedules in patients with nAMD (particularly if they are in the first 2 years of treatment), new patients with significant vision
loss, neovascular glaucoma, and monocular or quasi-monocular patients (only one eye > 20/40)
• Consider postponement of appointments for non-monocular patients, except patients with significant vision loss from recent DME, proliferative diabetic
retinopathy, acute-phase RVO, and ischemic RVO who should not be postponed
• Avoid prolonged treatment postponement (> 4–6 months) and reassess the situation regularly (within 2–3 months)
• Patients with DME and BRVO who already had their treatment postponed > 6 months during the initial wave of the COVID-19 pandemic should have their
treatment maintained
Reducing exposure during the patient examination
• Limit the use of OCT examinations and special instruments unless they are critical to decision-making
Treatment regimen considerations
• Avoid treatment regimens and regimen changes that require frequent monitoring to adjust dosing intervals
• Avoid switching treatment regimen unless there is a clear lack of response
• Avoid changing treatment intervals in patients with nAMD who are responding to a fixed-dose regimen
• Consider reverting to the last effective treatment interval and use this for fixed dosing in patients with AMD receiving variable-interval treatment regimens
o Reassure patients that fixed-dose anti-VEGF regimens are an effective way of delivering treatment [7, 13, 14]
• Maintain the loading phase schedule and select longer-acting therapies for new patients
• Only consider reimplantation of a dexamethasone implant in patients with DME/RVO if they are responding well and have a history of normal intraocular
pressure under such treatment
• Consider panretinal photocoagulation instead of intravitreal anti-VEGF for patients with severe PDR
Extreme epidemic pressure situationsc, in addition to all the above recommendations
Prioritizing patients according to medical need
• Postpone non-urgent appointments where there is capacity to reschedule within ≤ 4–6 months
• Prioritize and maintain treatment schedules in patients with nAMD (particularly if they are in the first 2 years of treatment), new patients with significant vision
loss, neovascular glaucoma, and monocular or quasi-monocular patients (only one eye > 20/40)
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Reducing exposure during the patient examination
In addition to stringent hygiene measures, use of PPE, and
physical distancing between staff and patients where appro-
priate, patient examinations should be kept as brief as possible
(Table 1). Use of plastic/plexiglass shields affixed to slit lamps
and optical coherence tomography may offer further protec-
tion during these examinations, in addition to the use of
masks. Given the potential risk of contamination, taping the
upper edges of the face mask during intravitreal injection pro-
cedures should be considered to prevent air jets from radiating
towards the eyes [22].
High epidemic pressure situations
High epidemic pressure indicates situations where the Rt is ~ 1
and/or there are many clusters of COVID-19-positive people
present in the community. The following considerations are
applicable for situations where the risk of contracting COVID-
19 is high but hospital resources are not yet strained.
Recommendations for situations of high epidemic pressure
are also valid in situations with a higher alert level, where
the Rt rises above 1 and hospital resources are strained,
resulting in the need for patient prioritization.
Prioritizing patients according to medical need
In situations where there is a high presence of COVID-19 in
the community, additional safety measures should be imple-
mented, such as pre-screening patients by phone to determine
whether they have symptoms consistent with COVID-19 or
have been recently exposed to the virus (Table 1).
High epidemic pressure may result in the need for post-
ponement of non-urgent appointments, guidance for which
has been previously published [1]. Patients with certain con-
ditions may be at greater risk of vision deterioration or perma-
nent vision loss with treatment delay and should have their
treatment maintained (Table 1). Previous studies have sug-
gested that, in the short term, DME and BRVO cases may
be less likely to suffer irreversible vision loss [6, 7], which
may make certain patients suitable candidates for treatment
delay. However, as these patients may have already had their
treatment postponed > 6 months during the initial wave of the
COVID-19 pandemic, further deferral could lead to perma-
nent visual changes and therefore these patients should have
their treatment maintained wherever possible.
Reducing exposure during the patient examination
In addition to the recommended guidance for low epidemic
pressure situations (Table 1), it may be appropriate during
high epidemic pressure to limit the use of optical coherence
tomography examinations and special instruments (Table 1),
unless they are deemed critical for the management of a par-
ticular patient.
Treatment regimen considerations
Simplification of treatment regimens and avoidance of regi-
men changes that require frequent monitoring are recom-
mended as additional measures to reduce exposure and free
up healthcare resources during periods of high epidemic pres-
sure. Guidance on suggested approaches to minimize the need
for monitoring is provided in Table 1.
Due to the increased likelihood that patients will be unable
to attend regular appointments during the pandemic,
panretinal photocoagulation may be a preferable treatment
choice for patients with severe proliferative diabetic
Table 1 (continued)
• Consider referral to a non-hospital-based clinic or ambulatory surgical center
• Consider using telemedicine consultations for patient triaging and to monitor those whose in-person appointments have been postponed
o It may be acceptable in the short term (≤ 4–6 months) to monitor the disease on function only
• Consider offering home care for patients unable to attend in-person appointments (e.g., under lockdown)
Reducing exposure during the patient examination
• Avoid thorough visual acuity testing of every patient
o A simple self-performed test such as a near-reading chart may be sufficient to flag an important visual change requiring further investigation
aRt significantly < 1 without herd immunity through mass vaccination; some physical distancing measures are likely to be implemented. These
recommendations are also valid in situations with a higher alert level
bRt ~ 1 and/or many clusters of COVID-19-positive people are present in the community but there is no strain on hospital resources. These recom-
mendations are also valid in situations with a higher alert level
cRt significantly > 1 and hospital resources are under significant pressure; lockdownmeasures may be in place. These recommendations are only valid in
this alert level
AMD age-related macular degeneration, BRVO branch retinal vein occlusion, DME diabetic macular edema, nAMD neovascular age-related macular
degeneration, OCT optical coherence tomography, PDR proliferative diabetic retinopathy, PPE personal protective equipment, RVO retinal vein
occlusion, VEGF vascular endothelial growth factor
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retinopathy to reduce the potential risk of developing traction-
al retinal detachment.
It is important to reassure patients who are switched to a
fixed-dose regimen as a result of the pandemic of the validity
and efficacy of using this approach to deliver their anti-VEGF
therapy [7, 13, 14].
Extreme epidemic pressure situations
Extreme epidemic pressure indicates situations where the Rt is
significantly > 1 and hospital resources are likely to be under
significant pressure. In such circumstances, where the spread
of COVID-19 is accelerating rapidly, it is likely that lockdown
measures are implemented within the local area or country.
The following recommendations are only for consideration in
instances of extreme epidemic pressure and where the risk–
benefits have been carefully weighed.
Prioritizing patients according to medical need
Where the risk of infection is high and hospital resources are
strained, consider postponing non-urgent appointments where
there is capacity to reschedule within ≤ 4–6 months (Table 1).
Additional measures, including implementation of
telemedicine consultations, referral of patients to non-
hospital-based settings, or offering home care, should
be considered where possible to reduce footfall at hos-
pitals and limit the risk of exposure of vulnerable pa-
tients to COVID-19. Telemedicine consultations are en-
couraged for patients who have been deprioritized to
enable visual function monitoring until they are able to
attend an in-person appointment, which should ideally
be within ≤ 4–6 months (Table 1).
Reducing exposure during the patient examination
In situations of extreme epidemic pressure, it may be accept-
able to avoid full visual acuity testing of every patient in order
to reduce the examination time and any potential exposure.
Use of a near-reading chart or performance of a brief visual
acuity test may be sufficient to flag any visual changes that
require further investigation (Table 1).
Conclusion
Management strategies for ophthalmic care of patients with
retinal disease while COVID-19 remains a threat should be
reassessed at regular intervals and adjusted in response to local
infection rates and the availability of healthcare resources. The
long-term impact of the delays or cancellations of ophthalmol-
ogy appointments during the initial wave of the COVID-19
pandemic is still to be determined. As long as local infection
rates remain low, ophthalmologists should aim to practice at
as close to normal operating levels as possible, to limit the risk
of irreversible vision loss while ensuring that adequate safety
protocols, including PPE and physical distancing, are in place.
In areas where there are many COVID-19-positive clusters
or where the number of cases is increasing exponentially,
measures to ensure the safety of patients and staff, and the
sustainability of healthcare resources, should be intensified
as appropriate. In such situations, complex intravitreal anti-
VEGF treatment regimens requiring frequent monitoring and
dose adjustment should be simplified, and treatment should be
prioritized for those at greatest risk of irreversible vision loss.
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